Education
About Us
Working with TipRanks
Follow Us
Eledon Pharmaceuticals (ELDN)
NASDAQ:ELDN
ELDN Stock Chart & Stats
$2.06
-$0.17(-3.66%)
At close: 4:00 PM EST
$2.06
-$0.17(-3.66%)
Day’s Range― - ―
52-Week Range$2.32 - $5.17
Previous CloseN/A
Volume121.23K
Average Volume (3M)1.58M
Market Cap
$241.32M
Enterprise ValueN/A
Total Cash (Recent Filing)$107.57M
Total Debt (Recent Filing)$803.00K
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Mar 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding59,881,775
10 Day Avg. Volume1,729,252
30 Day Avg. Volume1,577,761
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.23
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$7.50Price Target Upside264.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug Safety ProfileTegoprubart continues to demonstrate a differentiated safety profile relative to the current standard of care, with markedly fewer metabolic, neurologic, and cardiovascular toxicities than typically observed with tacrolimus.
Financial StabilityManagement expects existing capital to fund operations to the end of 2026.
Regulatory ProgressEledon plans to pursue a Phase III program with tegoprubart in late 2026 following upcoming discussions with regulators.
Bears Say
Efficacy ConcernsThe eGFR benefit was not statistically significant vs. tacrolimus, which outperformed historical benchmarks.
Market Penetration ChallengesThe lack of eGFR superiority vs. tacrolimus is definitely a disappointment, leading to a reduction in market penetration assumptions for tegoprubart.
Study LimitationsThe study is 80% powered to detect a 9% delta between the two immunosuppressants.
Eledon Pharmaceuticals News
ELDN FAQ
What was Eledon Pharmaceuticals’s price range in the past 12 months?
Eledon Pharmaceuticals lowest stock price was $2.31 and its highest was $5.17 in the past 12 months.
What is Eledon Pharmaceuticals’s market cap?
Eledon Pharmaceuticals’s market cap is $241.32M.
When is Eledon Pharmaceuticals’s upcoming earnings report date?
Eledon Pharmaceuticals’s upcoming earnings report date is Mar 19, 2026 which is in 131 days.
How were Eledon Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Eledon Pharmaceuticals overvalued?
According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued.
Does Eledon Pharmaceuticals pay dividends?
Eledon Pharmaceuticals does not currently pay dividends.
What is Eledon Pharmaceuticals’s EPS estimate?
Eledon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eledon Pharmaceuticals have?
Eledon Pharmaceuticals has 59,881,775 shares outstanding.
What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eledon Pharmaceuticals?
Currently, no hedge funds are holding shares in ELDN
Eledon Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (264.08% Upside)
$7.50 (264.08% Upside)
Blogger Sentiment
Bullish
ELDN Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.13%
12-Months-Change
Fundamentals
Return on Equity
-16.20%
Trailing 12-Months
Asset Growth
20.27%
Trailing 12-Months
Company Description
Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
ELDN Stock 12 Month Forecast
Average Price Target
$7.50
▲(264.08% Upside)
Technical Analysis
Tvardi Therapeutics
―
Editas Medicine
―
Annexon Biosciences
―
Design Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
22.43%
Insiders
7.60% Mutual Funds
0.07% Other Institutional Investors
61.58% Public Companies and
Individual Investors